About: Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis
Creator	Marx, Gernot Dreher, Michael Kleines, Michael Bickenbach, Johannes Brümmendorf, Tim Cornelissen, Christian Jost, Edgar Koschmieder, Steffen Marx, Nikolaus Müller, Tobias Schulze-Hagen, Maximilian
Source	Medline; PMC
abstract	COVID‐19 carries a high risk of severe disease course, particularly in patients with comorbidities. Therapy of severe COVID‐19 infection has relied on supportive intensive care measures. More specific approaches including drugs that limit the detrimental “cytokine storm”, such as Janus‐activated kinase (JAK) inhibitors, are being discussed. Here, we report a compelling case of a 55‐yo patient with proven COVID‐19 pneumonia, who was taking the JAK1/2 inhibitor ruxolitinib in‐label for co‐existing primary myelofibrosis for 15 months prior to coronavirus infection. The patient had significant comorbidities, including chronic kidney disease, arterial hypertension, and obesity, and our previous cohort suggested that he was thus at high risk for acute respiratory distress syndrome (ARDS) and death from COVID‐19. Since abrupt discontinuation of ruxolitinib may cause fatal cytokine storm and ARDS, ruxolitinib treatment was continued and was well tolerated, and the patient´s condition remained stable, without the need for mechanical ventilation or vasopressors. The patient became negative for SARS‐CoV‐2 and was discharged home after 15 days. In conclusion, our report provides clinical evidence that ruxolitinib treatment is feasible and can be beneficial in patients with COVID‐19 pneumonia, preventing cytokine storm and ARDS.
has issue date	2020-06-27(xsd:dateTime)
bibo:doi	10.1111/ejh.13480
bibo:pmid	32593209
has license	no-cc
sha1sum (hex)	f928f27514b517bbf5914d949a655c4c629e8880
schema:url	https://doi.org/10.1111/ejh.13480
resource representing a document's title	Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis
has PubMed Central identifier	PMC7361537
has PubMed identifier	32593209
schema:publication	Eur J Haematol
resource representing a document's body	covid:f928f27514b517bbf5914d949a655c4c629e8880#body_text
is schema:about of	named entity 'mild' named entity 'Case' named entity 'Report' named entity 'Title' named entity 'CLINICAL COURSE' named entity 'risk factors' named entity 'word count' named entity 'cytokine storm' named entity 'JAK' named entity 'pneumonia' named entity 'interleukin-6' named entity 'tachycardia' named entity 'pro-inflammatory cytokines' named entity 'fever' named entity 'COVID-19' named entity 'toxicity' named entity 'hypoxia' named entity 'polycythemia vera' named entity 'general practitioner' named entity 'COVID-19 testing' named entity 'treatment of patients' named entity 'tuberculosis' named entity 'ruxolitinib' named entity 'COVID' named entity 'PCR' named entity 'C-reactive protein' named entity 'tachycardia' named entity 'fever' named entity 'JAK inhibitors' named entity 'comorbidities' named entity 'hepatitis' named entity 'COVID' named entity 'ruxolitinib' named entity 'single-blind' named entity 'ruxolitinib' named entity 'treatment options' named entity 'COVID' named entity 'pneumonia' named entity 'ruxolitinib' named entity 'ruxolitinib' named entity 'obesity' named entity 'pro-inflammatory cytokines' named entity 'splenomegaly' named entity 'Computed tomography' named entity 'cytokine storm' named entity 'liver toxicity' named entity 'Manuscript' named entity 'ruxolitinib' named entity 'COVID-19 infection' named entity 'COVID' named entity 'comorbidities' named entity 'pneumonia' named entity 'cytokine storm' named entity 'Case Report' named entity 'COVID-19' named entity 'ruxolitinib' named entity 'ruxolitinib' named entity 'inflammation' named entity 'COVID' named entity 'macrophage activation syndrome' named entity 'macrophage' named entity 'infection' named entity 'CALR' named entity 'ruxolitinib' named entity 'Janus kinase 1' named entity 'physical exam' named entity 'IL-6R' named entity 'CKD' named entity 'intensive care unit' named entity 'MPN' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software